Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Ligand Pharmaceuticals Inc

NASDAQ: LGND · Life Sciences · 11 alerts · CIK 886163

Share price
$301.71Close, Nov 16
Market cap
$6.04B
Shares outstanding
20MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ligand Pharmaceuticals Inc filings on SEC EDGAR ↗

4:32 PM ET Form 4
Insider Selling

Ligand Pharmaceuticals Insider John W. Kozarich Sells $162K of Stock

John W. Kozarich sold 500 shares of Ligand Pharmaceuticals Inc at $325.00 a share, worth $162K in total on Nov 12, 2026. Shares held after the trade: 42,122 (-1.2%).

Value
$162K
Shares
500
Price
$325.00
Holding change
-1.2%
Trade date
Nov 12, 2026
4:26 PM ET Form 4
Insider Selling

Ligand Pharmaceuticals Insider Martine Zimmermann Sells $636K of Stock

Martine Zimmermann sold 2,000 shares of Ligand Pharmaceuticals Inc at $318.17 a share, worth $636K in total on Nov 12, 2026. Shares held after the trade: 1,782 (-52.9%).

Value
$636K
Shares
2,000
Price
$318.17
Holding change
-52.9%
Trade date
Nov 12, 2026
4:49 PM ET Form 4
Insider Selling

Ligand Pharmaceuticals Insider Jason Aryeh Sells $957K of Stock

Jason Aryeh sold 2,990 shares of Ligand Pharmaceuticals Inc at $319.99 to $320.20 a share (average $320.05) in 5 transactions, worth $957K in total on Nov 10, 2026. Shares held after the trade: 105,476 (-0.5%).

Value
$957K
Shares
2,990
Average price
$320.05
Holding change
-0.5%
Trade date
Nov 10, 2026
5:42 PM ET Form 4
Insider Selling

Ligand Pharmaceuticals Insider Jason Aryeh Sells $90.2K of Stock

Jason Aryeh sold 282 shares of Ligand Pharmaceuticals Inc at $319.99 a share, worth $90.2K in total on Nov 4, 2026. Shares held after the trade: 108,476 (-0.3%).

Value
$90.2K
Shares
282
Price
$319.99
Holding change
-0.3%
Trade date
Nov 4, 2026
4:23 PM ET Form 4
Insider Selling

Ligand Pharmaceuticals CLO & Secretary Andrew Reardon Sells $1.57M of Stock

Andrew Reardon, CLO & Secretary, sold 5,000 shares of Ligand Pharmaceuticals Inc at $307.39 to $323.14 a share (average $313.22) in 13 transactions, worth $1.57M in total on Nov 2, 2026. Shares held after the trade: 31,854 (-0.4%).

Value
$1.57M
Shares
5,000
Average price
$313.22
Role
CLO & Secretary
Holding change
-0.4%
Trade date
Nov 2, 2026
7:39 PM ET Form 4
Insider Selling

Ligand Pharmaceuticals Insider Jason Aryeh Sells $676K of Stock

Jason Aryeh sold 2,111 shares of Ligand Pharmaceuticals Inc at $317.74 to $320.49 a share (average $320.30) in 6 transactions, worth $676K in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 108,758 (-0.6%).

Value
$676K
Shares
2,111
Average price
$320.30
Holding change
-0.6%
Trade date
Oct 30, 2026 to Nov 2, 2026
4:47 PM ET 10-Q
Financial Results

Ligand Pharmaceuticals Q3 2026 Results: Net Loss of $28.5M

For the nine months ended September 30, 2026, Ligand Pharmaceuticals reported total revenues and income of $194.2 million and net income of $6.7 million, a decrease from $79.7 million in the prior year period. The company significantly expanded its balance sheet through the acquisition of XOMA, resulting in total assets increasing to $2.24 billion compared to $1.56 billion at year-end 2025.

Key figure
Net loss $28.5M
7:15 AM ET 8-K
Financial Results

Ligand Pharmaceuticals Financial Results

Ligand Pharmaceuticals reported Q3 2026 financial results, highlighted by a 51% year-over-year increase in royalty revenue to $70.3 million, driven by the XOMA portfolio and commercial momentum of Filspari. The company raised its full-year 2026 adjusted diluted EPS guidance to a range of $9.50 to $9.75 while reaffirming its total revenue guidance.

Term
Q3 2026

“Ligand delivered another strong quarter, with royalty revenue growing 51% year-over-year, driven by contribution from the XOMA portfolio and continued commercial momentum across our key royalty assets, including Filspari.”

Todd Davis, CEO of Ligand

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.